Efavirenz/emtricitabine/tenofovir

Efavirenz/emtricitabine/tenofovir disoproxil
Combination of
Efavirenz	non-nucleoside reverse transcriptase inhibitor
Emtricitabine	nucleoside analog reverse transcriptase inhibitor
Tenofovir disoproxil	nucleotide analog reverse transcriptase inhibitor
Clinical data
Trade names	Atripla, Viraday, others
Other names	tenofovir disoproxil fumarate/emtricitabine/efavirenz
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Atripla;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	J05AR06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	731772-50-2 ;
ChemSpider	none;
KEGG	D10851 ;
	(verify)

Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains efavirenz, emtricitabine, and tenofovir disoproxil. It can be used by itself or together with other antiretroviral medications. It is taken by mouth.

Common side effects include headache, trouble sleeping, sleepiness, and unsteadiness. Serious side effects may include high blood lactate levels, psychiatric symptoms, and enlargement of the liver. It should not be used in children. If used during the first trimester of pregnancy harm to the baby may occur.

Efavirenz/emtricitabine/tenofovir was approved for medical use in the United States in 2006, and in the European Union in 2007. It is on the World Health Organization's List of Essential Medicines. Efavirenz/emtricitabine/tenofovir is available as a generic medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.